•FDA grants IDE approval to Ciliatech for glaucoma implant study •Deep learning ties retinal features to Alzheimer's risk factors•Ocugen doses first patient in phase 3 GA gene therapy trial•Leadership watch: Samsara, Claris Bio, Staar Surgical, Wills Eye, and more•Study: Earlier RD surgery predicts stronger visual outcomes•FDA grants IDE approval to Ciliatech for glaucoma implant study •Deep learning ties retinal features to Alzheimer's risk factors•Ocugen doses first patient in phase 3 GA gene therapy trial•Leadership watch: Samsara, Claris Bio, Staar Surgical, Wills Eye, and more•Study: Earlier RD surgery predicts stronger visual outcomes
HEADLINES
FEATURED
Phase 1b/2a study to evaluate a bifunctional Wnt agonist and VEGF antagonist antibody that targets vascular leakage and promote retinal vascular integrity
Earn FREE CE 24/7 with Courses by Eyes On Eyecare
Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.
